

IVMB0232

Product Information

Product SKU: IVMB0232

Clone: A4.6.1

Target: VEGF

Size: 100 mg, 25 mg, 50 mg, 5.0 mg, 1.0 mg

Isotype: Human IgG1κ

Additional Information

Reactivity: Human

Host Species: Human

Antibody Type: Biosimilar Recombinant Human Monoclonal Antibody

Expression Host: HEK-293 Cells

Immunogen Information

Background: Bevacizumab is a monoclonal antibody that specifically recognizes vascular endothelial growth factor (VEGF). VEGF is a growth factor that participates in angiogenesis, vasculogenesis, and endothelial cell growth. It facilitates endothelial cell proliferation, cell migration, and the permeabilization of blood vessels. In addition, VEGF inhibits apoptosis. Bevacizumab neutralizes the biological activity of VEGF by preventing the interaction of VEGF with its receptors on the surface of endothelial cells, resulting in the regression of tumor vascularization, normalization of remaining tumor vasculature, and inhibition of the formation of new tumor vasculature, thus inhibiting tumor growth.¹ Anti-Human VEGF (Bevacizumab) utilizes the same variable regions from the therapeutic antibody Bevacizumab making it ideal for research projects.

Endotoxin Level: < 1.0 EU/mg as determined by the LAL method

Applications: B

Synonyms: Vascular Endothelial Growth Factor; VEGF-A; VEGFA; Vascular Permeability Factor; VPF

Antigen Distribution: VEGF is widely expressed in the thyroid, prostate, and various other tissues.

Immunogen: Recombinant human VEGF.

Formulation: This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium

or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Specificity:

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Bevacizumab. Bevacizumab recognizes both native and reduced human VEGF (isoform 165). This product is for research use only.

Product Preparation:

Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Storage & Handling:

Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.